152 related articles for article (PubMed ID: 27616074)
1. Quality by design (QbD) approach for design and development of drug-device combination products: a case study on flunisolide nasal spray.
Chudiwal SS; Dehghan MHG
Pharm Dev Technol; 2018 Dec; 23(10):1077-1087. PubMed ID: 27616074
[TBL] [Abstract][Full Text] [Related]
2. Quality by design approach for development of suspension nasal spray products: a case study on budesonide nasal suspension.
Chudiwal SS; Dehghan MH
Drug Dev Ind Pharm; 2016 Oct; 42(10):1643-52. PubMed ID: 26943653
[TBL] [Abstract][Full Text] [Related]
3. Development of sustained release gastro-retentive tablet formulation of nicardipine hydrochloride using quality by design (QbD) approach.
Chudiwal VS; Shahi S; Chudiwal S
Drug Dev Ind Pharm; 2018 May; 44(5):787-799. PubMed ID: 29198152
[TBL] [Abstract][Full Text] [Related]
4. QbD-enabled systematic development of gastroretentive multiple-unit microballoons of itopride hydrochloride.
Bansal S; Beg S; Asthana A; Garg B; Asthana GS; Kapil R; Singh B
Drug Deliv; 2016; 23(2):437-51. PubMed ID: 24865292
[TBL] [Abstract][Full Text] [Related]
5. Risk Assessment Integrated QbD Approach for Development of Optimized Bicontinuous Mucoadhesive Limicubes for Oral Delivery of Rosuvastatin.
Javed MN; Kohli K; Amin S
AAPS PharmSciTech; 2018 Apr; 19(3):1377-1391. PubMed ID: 29388027
[TBL] [Abstract][Full Text] [Related]
6. Quality by Design (QbD) Approach for Development of Co-Processed Excipient Pellets (MOMLETS) By Extrusion-Spheronization Technique.
Patel H; Patel K; Tiwari S; Pandey S; Shah S; Gohel M
Recent Pat Drug Deliv Formul; 2016; 10(3):192-206. PubMed ID: 27396400
[TBL] [Abstract][Full Text] [Related]
7. An integrated, quality by design (QbD) approach for design, development and optimization of orally disintegrating tablet formulation of carbamazepine.
Mishra SM; Rohera BD
Pharm Dev Technol; 2017 Nov; 22(7):889-903. PubMed ID: 27346282
[TBL] [Abstract][Full Text] [Related]
8. Elucidation of Formulation and Delivery Device-Related Effects on In Vitro Performance of Nasal Spray with Implication to Rational Product Specification Identification.
Grmaš J; Stare K; Božič D; Injac R; Dreu R
J Aerosol Med Pulm Drug Deliv; 2017 Aug; 30(4):230-246. PubMed ID: 28075184
[TBL] [Abstract][Full Text] [Related]
9. Development and in vitro evaluation of pH-independent release matrix tablet of weakly acidic drug valsartan using quality by design tools.
Saydam M; Takka S
Drug Dev Ind Pharm; 2018 Dec; 44(12):1905-1917. PubMed ID: 29969042
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of efficacy and safety of flunisolide hydrofluoroalkane for the treatment of asthma.
Corren J; Tashkin DP
Clin Ther; 2003 Mar; 25(3):776-98. PubMed ID: 12852702
[TBL] [Abstract][Full Text] [Related]
11. Implementation of Quality by Design for Formulation of Rebamipide Gastro-retentive Tablet.
Ha JM; Seo JW; Kim SH; Kim JY; Park CW; Rhee YS; Park ES
AAPS PharmSciTech; 2017 Nov; 18(8):3129-3139. PubMed ID: 28526986
[TBL] [Abstract][Full Text] [Related]
12. New formulation of aqueous flunisolide nasal spray in the treatment of allergic rhinitis: comparative assessment of safety, tolerability, and efficacy.
Ratner P; van Bavel J; Gross G; Bynum L; Munshi A
Allergy Asthma Proc; 1996; 17(3):149-56. PubMed ID: 8790827
[TBL] [Abstract][Full Text] [Related]
13. Application of quality by design (QbD) to formulation and processing of naproxen pellets by extrusion-spheronization.
Wang J; Kan S; Chen T; Liu J
Pharm Dev Technol; 2015 Mar; 20(2):246-56. PubMed ID: 25069591
[TBL] [Abstract][Full Text] [Related]
14. Allergic rhinitis in children: effects of flunisolide and disodium cromoglycate on nasal eosinophil cationic protein.
Sensi LG; Seri A; Siracusa A; Pertici L; Marcucci F
Clin Exp Allergy; 1997 Mar; 27(3):270-6. PubMed ID: 9088653
[TBL] [Abstract][Full Text] [Related]
15. Six-week trial of nebulized flunisolide nasal spray: efficacy in young children with moderately severe asthma.
Allen ED; Whitaker ER; Ryu G
Pediatr Pulmonol; 1997 Dec; 24(6):397-405. PubMed ID: 9448231
[TBL] [Abstract][Full Text] [Related]
16. A quality-by-design study to develop Nifedipine nanosuspension: examining the relative impact of formulation variables, wet media milling process parameters and excipient variability on drug product quality attributes.
Patel PJ; Gajera BY; Dave RH
Drug Dev Ind Pharm; 2018 Dec; 44(12):1942-1952. PubMed ID: 30027778
[TBL] [Abstract][Full Text] [Related]
17. Assessment of the influence factors on in vitro testing of nasal sprays using Box-Behnken experimental design.
Guo C; Stine KJ; Kauffman JF; Doub WH
Eur J Pharm Sci; 2008 Dec; 35(5):417-26. PubMed ID: 18832029
[TBL] [Abstract][Full Text] [Related]
18. A quality by design approach to understand formulation and process variability in pharmaceutical melt extrusion processes.
Patwardhan K; Asgarzadeh F; Dassinger T; Albers J; Repka MA
J Pharm Pharmacol; 2015 May; 67(5):673-84. PubMed ID: 25615235
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of symptom relief, nasal airflow, nasal cytology, and acceptability of two formulations of flunisolide nasal spray in patients with perennial allergic rhinitis.
Meltzer EO; Orgel HA; Bush RK; Haltom JR; Metzger WJ; Moss BA; Mitchell DQ; Ballas ZK; Seltzer JM; Shapiro GG
Ann Allergy; 1990 Jun; 64(6):536-40. PubMed ID: 2189319
[TBL] [Abstract][Full Text] [Related]
20. Quality by design approach for the preparation of fat-soluble vitamins lipid injectable emulsion.
Deng Y; Zhong G; Wang Y; Wang N; Yu Q; Yu X
Int J Pharm; 2019 Nov; 571():118717. PubMed ID: 31610279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
